Plain-English translation of NCT05451784 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called NUMARZU-001, which uses immune cells taken from your own tumor, grown in the laboratory, and then returned to your body to fight the cancer. The trial focuses on triple-negative breast cancer, a type that has limited treatment options and tends to be more aggressive. Researchers believe this personalized immune approach may help your body recognize and destroy cancer cells more effectively.
Triple-negative breast cancer is particularly difficult to treat because it lacks three markers that many other breast cancers have, leaving fewer targeted therapy options available. This trial exists to see whether using a patient's own immune cells—specifically those already primed to recognize their cancer—can offer a new hope for people with advanced disease.
You likely qualify if…
You likely don't qualify if…
First, researchers will take a small sample of your tumor (biopsy) to check if your cancer has enough of the right type of immune cells—this screening takes about 4 weeks, and you can continue your regular cancer treatment during this time. If you qualify, your immune cells will be removed, grown in larger numbers in the laboratory, and then infused back into your body along with supportive medications. You will need to visit the hospital for the treatment and follow-up visits to monitor how you respond.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Spain